Drug
Vibegron clinical trials
Also written MK-4618, RVT-901 and Gemtesa.
- studies test it
- 14
- open now
- 4
- in phase 3
- 6
- first study started
- 2011
Keep track of what changes. Save the vibegron studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2018 | 3 |
| 2019 | 2 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 3
- Phase 2
- 3
- Phase 3
- 6
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 4
Urovant Sciences GmbH (6) · Merck Sharp & Dohme LLC (4) · University of Missouri-Columbia (2) · Wake Forest University Health Sciences (1) · University of Alabama at Birmingham (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses vibegron is read from its arms, and is right about nine times in ten.
Testing it · 14
- Vibegron for ENergy Thinking and Resilience in AgingNot yet recruitingPhase 3Wake Forest University Health SciencesNCT06987383Written as Vibegron
- Impact of Early Aging and Menopause on the Vascular Responses to HypoxiaRecruitingEarly Phase 1University of Missouri-ColumbiaNCT06417177Written as Gemtesa
- Beta3-adrenergic Receptors and Cardiovascular Function in Aging WomenRecruitingEarly Phase 1University of Missouri-ColumbiaNCT07674680Written as Gemtesa
- Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CICRecruitingPhase 2/3Urovant Sciences GmbHNCT05491525Written as Vibegron
- Role of Combination Therapy in Women With Refractory Overactive BladderWithdrawnNot applicableUniversity of Alabama at BirminghamNCT06438861Written as Vibegron 75mg
- Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic HyperplasiaCompletedPhase 3Urovant Sciences GmbHNCT04103450Written as Vibegron
- Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)CompletedPhase 3Urovant Sciences GmbHNCT03902080Written as Vibegron
- Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel SyndromeCompletedPhase 2Urovant Sciences GmbHNCT03806127Written as Vibegron
- An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).CompletedPhase 3Urovant Sciences GmbHNCT03583372Written as Vibegron
- A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)CompletedPhase 3Urovant Sciences GmbHNCT03492281Written as vibegron
- A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)CompletedPhase 2Merck Sharp & Dohme LLCNCT01314872Written as Vibegron
- A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)CompletedPhase 1Merck Sharp & Dohme LLCNCT01737684Written as Vibegron
- A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)CompletedPhase 1Merck Sharp & Dohme LLCNCT01628042Written as Vibegron 100 mg
- A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)TerminatedPhase 1Merck Sharp & Dohme LLCNCT01500382Written as Vibegron
Given in every arm · 1 — vibegron is usual care beside what is tested
Codes
What other systems call vibegron · ClinicalTrials.gg INT000476
- UNII (FDA) M5TSE03W5UVIBEGRONConfirmed FDA, Wikidata
- RxNorm 2472254One source FDA
- Wikidata Q27283524vibegronConfirmed FDA, Wikidata
- NCI Thesaurus C152872VibegronOne source FDA
- DrugBank DB14895One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | M5TSE03W5U | VIBEGRON | Confirmed FDA, Wikidata |
| RxNorm | 2472254 | — | One source FDA |
| Wikidata | Q27283524 | vibegron | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152872 | Vibegron | One source FDA |
| DrugBank | DB14895 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.